Floatz logo

Blinatumomab

Acute Leukemia

SWOG Cancer Research Networkmonoclonal_antibodyPhase 2Active
CCC
51/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
73/ 100

Competitive context

52 Active assets in the Acute Leukemia cohort.

Asset / SponsorPhaseRating
Fludarabine
Sawa Ito, MD
Phase 2/3BB
Cyclophosphamide
Sawa Ito, MD
Phase 4BB
Cytosin-Arabinosid
Janssen Research & Development, LLC
Phase 2/3BB
Busulphan
Sawa Ito, MD
Phase 4BB
METHOTREXATE
SWOG Cancer Research Network
Phase 3BB

View all 50 →

Same molecule, other indications

Blinatumomab is also rated in:

precursor B-cell acute lymphoblastic leukemiaDormant
BBB
Indicative ·
72 / 100
View asset →
B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)Dormant
BBB
Indicative ·
72 / 100
View asset →
Precursor B-Cell Acute Lymphoblastic LeukemiaDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →